Cassava Sciences Inc (SAVA)

$3.57 -0.06 (-1.65%)
Market Cap 175.36M
Revenue (ttm) 0.00
Net Income (ttm) -24.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,658,800
Avg Vol 2,364,754
Day's Range N/A - N/A
Shares Out 48.31M
Stochastic %K 90%
Beta -0.98
Analysts Strong Buy
Price Target $2.00

Company Profile

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company w...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 501 2444
Address:
6801 N. Capital of Texas Highway, Suite 300 Building 1, Austin, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 7 at 2:23 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SAVA Current Share Price: $3.78 Contracts: $SAVA January 15, 2027 $4 Calls Scale in: $1.37- $1.68 Scale out: $2.13-$2.75 Can Easily Capture: 60% ROI Blended DTE: 466 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
BullseyeStock
BullseyeStock Oct. 7 at 1:50 AM
Looking for the next monster runner?? Make sure to have ticker PRHI on watch for tmr!!🚨 PRHI is one of those tickers that has the recipe to see a massive rally. Had a very strong close after hours with a close like that, I wont be surprised if this heads to $4+ tmr. Don't miss out PRHI bulls!!🚨 $SAVA $GTBP $CGTK $STKH ww..
0 · Reply
WhosYourDaddy_
WhosYourDaddy_ Oct. 6 at 7:23 PM
$SAVA
0 · Reply
Swai
Swai Oct. 6 at 7:20 PM
$SAVA power hour?
0 · Reply
BambooC
BambooC Oct. 6 at 6:43 PM
$SAVA $SPRB goose bump yet?
0 · Reply
WhosYourDaddy_
WhosYourDaddy_ Oct. 6 at 6:25 PM
$SAVA Move Bitch all in at $3.59
0 · Reply
stockusfrance
stockusfrance Oct. 6 at 6:11 PM
Comment $SAVA ? Vous allez bien ?
1 · Reply
BambooC
BambooC Oct. 6 at 6:10 PM
$SPRB $SAVA 👀👀
0 · Reply
Justrise07
Justrise07 Oct. 6 at 6:08 PM
$SAVA PR after hours? Last 1 hour to load big $RR
0 · Reply
BambooC
BambooC Oct. 6 at 5:27 PM
$SAVA need the first 5 folders before fomos jumping in
0 · Reply
Latest News on SAVA
Cassava Reports Q2 2025 Financials Results and Provides Business Update

Aug 14, 2025, 7:30 AM EDT - 7 weeks ago

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Aug 7, 2025, 7:30 AM EDT - 2 months ago

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Aug 4, 2025, 7:30 AM EDT - 2 months ago

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

Jun 30, 2025, 7:00 AM EDT - 3 months ago

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

May 1, 2025, 7:30 AM EDT - 5 months ago

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Apr 21, 2025, 4:30 PM EDT - 6 months ago

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Mar 26, 2025, 3:49 PM EDT - 6 months ago

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

Mar 25, 2025, 10:42 AM EDT - 6 months ago

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Mar 25, 2025, 8:05 AM EDT - 6 months ago

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:30 AM EST - 7 months ago

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

Feb 9, 2025, 10:45 AM EST - 8 months ago

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Feb 7, 2025, 12:08 PM EST - 8 months ago

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Feb 3, 2025, 5:45 AM EST - 8 months ago

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Jan 23, 2025, 2:47 PM EST - 9 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Cassava Sciences Provides a Business Update

Jan 7, 2025, 4:30 PM EST - 9 months ago

Cassava Sciences Provides a Business Update

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

Dec 23, 2024, 5:45 AM EST - 10 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Dec 18, 2024, 10:53 AM EST - 10 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Dec 13, 2024, 1:16 PM EST - 10 months ago

Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Bronstein, Gewirtz & Grossman, LLC Encourages Cassava Sciences, Inc. (SAVA) Shareholders to Inquire about Securities Investigation

Dec 10, 2024, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Cassava Sciences, Inc. (SAVA) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Shareholders to Connect

Dec 9, 2024, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Shareholders to Connect

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 7 at 2:23 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SAVA Current Share Price: $3.78 Contracts: $SAVA January 15, 2027 $4 Calls Scale in: $1.37- $1.68 Scale out: $2.13-$2.75 Can Easily Capture: 60% ROI Blended DTE: 466 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
BullseyeStock
BullseyeStock Oct. 7 at 1:50 AM
Looking for the next monster runner?? Make sure to have ticker PRHI on watch for tmr!!🚨 PRHI is one of those tickers that has the recipe to see a massive rally. Had a very strong close after hours with a close like that, I wont be surprised if this heads to $4+ tmr. Don't miss out PRHI bulls!!🚨 $SAVA $GTBP $CGTK $STKH ww..
0 · Reply
WhosYourDaddy_
WhosYourDaddy_ Oct. 6 at 7:23 PM
$SAVA
0 · Reply
Swai
Swai Oct. 6 at 7:20 PM
$SAVA power hour?
0 · Reply
BambooC
BambooC Oct. 6 at 6:43 PM
$SAVA $SPRB goose bump yet?
0 · Reply
WhosYourDaddy_
WhosYourDaddy_ Oct. 6 at 6:25 PM
$SAVA Move Bitch all in at $3.59
0 · Reply
stockusfrance
stockusfrance Oct. 6 at 6:11 PM
Comment $SAVA ? Vous allez bien ?
1 · Reply
BambooC
BambooC Oct. 6 at 6:10 PM
$SPRB $SAVA 👀👀
0 · Reply
Justrise07
Justrise07 Oct. 6 at 6:08 PM
$SAVA PR after hours? Last 1 hour to load big $RR
0 · Reply
BambooC
BambooC Oct. 6 at 5:27 PM
$SAVA need the first 5 folders before fomos jumping in
0 · Reply
BambooC
BambooC Oct. 6 at 5:26 PM
$SAVA shorts can’t fight Wall Street number 1 biotech analyst veteran PhD 🤑🔥🤘
0 · Reply
SPYmyQQQ
SPYmyQQQ Oct. 6 at 4:43 PM
💊 🚀 $SAVA up ⬆️83.73% since our entry $2.09 on Sep 15, 2025 👉 FREE TRIAL! spymyqqq.com/join/ Time-stamped signals. NO B.S.!
0 · Reply
MoonShine007
MoonShine007 Oct. 6 at 4:40 PM
$SAVA what’s happening? Frozen?
0 · Reply
ill_Freaky_na_na
ill_Freaky_na_na Oct. 6 at 4:27 PM
$SAVA $10 for Christmas would be a great gift from Santa
0 · Reply
joaorodrigues008
joaorodrigues008 Oct. 6 at 3:58 PM
$SAVA Going to 10$ before december?
0 · Reply
xohan84
xohan84 Oct. 6 at 3:33 PM
$SAVA Sorry folks I don't have a stick long enough
0 · Reply
BambooC
BambooC Oct. 6 at 2:41 PM
$SAVA Dr. Piros was ranked #1 biotech analyst by Wall Street Journal before. 🤑😂🔥📈 8+ coming!?
0 · Reply
0N1Bull
0N1Bull Oct. 6 at 2:36 PM
$SAVA $8 PT Lucid Capital Markets https://m.investing.com/news/analyst-ratings/cassava-sciences-stock-initiated-with-buy-rating-at-lucid-capital-markets-93CH-4272217?ampMode=1
0 · Reply
BambooC
BambooC Oct. 6 at 2:34 PM
$SAVA no one is selling
0 · Reply
MarcoFla99
MarcoFla99 Oct. 6 at 2:28 PM
$SAVA WHY? LUCID CAPITAL MARKETS Initiates Coverage On Cassava Sciences with Buy Rating, Announces Price Target of $8
1 · Reply
whydididothat
whydididothat Oct. 6 at 2:22 PM
$SAVA end of year?
0 · Reply
DK_72
DK_72 Oct. 6 at 2:00 PM
$SAVA but if there is one , we should hear it 🔜
0 · Reply